Today: 5 April 2026
Subscribe
Browse Category

Stock Market 8 October 2025 - 9 October 2025

FTSE 100’s Record Run: Inside London’s Blue-Chip Rally and What’s Next

FTSE 100’s Record Run: Inside London’s Blue-Chip Rally and What’s Next

The FTSE 100 closed at a record high near 9,548 in early October, up 15–17% year-to-date, led by surges in banks, miners, and healthcare stocks. Gains followed strong earnings, regulatory relief, and gold topping $4,000/oz. A weak pound boosted international firms’ profits. Political shifts and a new UK-India trade deal also moved markets, while Middle East tensions kept oil and gold prices elevated.
9 October 2025
······
AMD’s AI Mega-Deal Sparks Stock Surge – Inside the OpenAI Partnership, New Chips & Showdown with Rivals

AMD Stock Skyrockets on AI Mega-Deal: Inside the 2025 Rally, Financials & Rivalry

AMD shares have jumped nearly 93% in 2025, hitting a record $233 after announcing a multi-year deal to supply AI chips to OpenAI. The pact could bring in tens of billions in annual revenue and gives OpenAI warrants for up to 10% of AMD stock. Q2 revenue rose 32% to $7.7 billion, but gross margin fell to 43%. Analysts raised price targets, though some warn AMD remains overvalued compared to Nvidia.
8 October 2025
····
Duolingo Stock Surges on AI Buzz – Latest Price, Bold Forecasts & Big Risks in 2025

Duolingo Stock Surges on AI Buzz – Latest Price, Bold Forecasts & Big Risks in 2025

Duolingo shares jumped 5% to around $339 on Oct. 8, rebounding from lows earlier in the week but still far below last year’s $545 high. The rally followed news of new AI features and partnerships, while co-founder Severin Hacker sold nearly all his stake for $3.2 million on Oct. 6. Q2 revenue rose 41% to $252.3 million, with paid subscribers up 37% to 10.9 million. Duolingo reports Q3 earnings on Nov. 5.
8 October 2025
··
Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – What Investors Need to Know

Tempus AI (TEM) Stock Skyrockets on AI Healthcare Breakthroughs – What Investors Need to Know

Tempus AI shares closed at a record $102.31 on October 8, 2025, nearly tripling year-to-date after FDA clearance for new AI diagnostics and the $81.3 million acquisition of Paige. Q2 revenue surged 89.6% to $314.6 million, with net losses narrowing and positive adjusted EBITDA forecast for 2025. Market cap stands near $17 billion.
8 October 2025
···
Cipher Mining (CIFR) Stock Skyrockets on AI Pivot & Bitcoin Boom – Next Crypto Powerhouse?

Cipher Mining (CIFR) Stock Skyrockets on AI Pivot & Bitcoin Boom – Next Crypto Powerhouse?

Cipher Mining shares traded near all-time highs at $15–$16 on Oct. 8, 2025, after surging 320% year-to-date. The company signed a 10-year deal in September to host 168 MW of high-performance computing for Fluidstack at its new Barber Lake site. Cipher’s hashrate reached 16.8 EH/s in mid-2025, with plans to expand to 23.5 EH/s by Q3. Market cap stood between $5.4 and $6.0 billion.
8 October 2025
···
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Adaptimmune Therapeutics shares soared 42% to around $0.20 on Oct. 8, 2025, after weeks of extreme volatility and trading volumes topping 705 million shares. The company sold its four main cell therapy programs, including newly approved Tecelra, for $55 million upfront in July to pay off debt and cut its workforce by 62%. Weiss Ratings issued a rare “Sell (E+)” on Oct. 8. No new products have been announced this month.
8 October 2025
·
CrowdStrike Stock Skyrockets Amid Cybersecurity Boom – Is the Rally Justified? (2025 Update)

CrowdStrike Stock Skyrockets Amid Cybersecurity Boom – Is the Rally Justified? (2025 Update)

CrowdStrike shares trade near $500 after a 65% year-on-year surge, giving the cybersecurity firm a $125 billion market cap and a valuation of about 135 times forward earnings. The company agreed in August to buy Onum for $290 million and unveiled new AI-powered security features in September. Revenue rose 21% last quarter to $740 million with EPS of $0.93. Wall Street remains broadly bullish, with most analysts rating the stock a Buy.
8 October 2025
···
Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna closed at $27.34 on Oct 7, 2025, with a market cap near $11 billion. Q2 revenue fell 41% year-over-year to $142 million, and the company posted a net loss of $0.8 billion. U.S. and EU regulators limited updated COVID booster use, narrowing near-term revenue prospects. Analysts’ 12-month price targets remain high, but sales forecasts have repeatedly missed expectations.
8 October 2025
··
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia’s NTLA-2001 gene editing therapy cut TTR protein by about 90% for three years in transthyretin amyloidosis patients, with improved outcomes and no new safety issues, according to data presented Sept. 25 and published in NEJM. Enrollment finished for the Phase 3 HAELO trial of NTLA-2002, with top-line results expected in 1H 2026. Intellia stock is up over 60% in 2025. Q2 revenue more than doubled to $14.25 million.
8 October 2025
···
TSMC Stock Soars on AI Boom: Record Highs, Big Ambitions & Geopolitical Risks (Oct 2025 Update)

TSMC Stock Soars on AI Boom: Record Highs, Big Ambitions & Geopolitical Risks (Oct 2025 Update)

TSMC shares hover near record highs, up about 45% in 2024, as Q2 revenue surged 44% year-on-year to $30.1 billion on AI chip demand. Morgan Stanley and Bank of America raised targets ahead of Q3 results due Oct. 16. Taiwan rejected U.S. calls to split chip output, while Chinese drills raised energy security concerns. TSMC aims to start 2nm chip mass production by late 2025.
8 October 2025
··
Cisco’s $2B AI Windfall: New Tech, Stock Surge & What’s Next for CSCO

Cisco’s $2B AI Windfall: New Tech, Stock Surge & What’s Next for CSCO

Cisco unveiled a 51.2 Tbps router and Silicon One P200 chip for AI data centers on Oct. 8, 2025, with Microsoft and Alibaba as initial buyers. Fiscal 2025 revenue reached $56.7 billion, up 5%, and AI-focused orders topped $2 billion. Shares trade near $69 with a 2.4% dividend yield. Wall Street rates the stock a “Moderate Buy,” with an average 12-month price target of $74–75.
8 October 2025
··
UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

UnitedHealth Group closed near $372 on Oct. 8, up over 2%, but remains far below its April high of $630. The company reported $422.8 billion in trailing 12-month revenue and $21.3 billion net income. Analysts raised price targets after recent upgrades, but the stock faces pressure from rising medical costs and regulatory probes. Third-quarter results are due Oct. 28, with guidance cut to $14.65 per share.
8 October 2025
·
Palo Alto Networks’ AI-Fueled Surge: Stock Soars on Cybersecurity Boom, Bold Forecasts & Big Deals

Palo Alto Networks’ AI-Fueled Surge: Stock Soars on Cybersecurity Boom, Bold Forecasts & Big Deals

Palo Alto Networks traded near $216 on October 8, 2025, approaching multi-month highs and a $135–140 billion market cap. Unit 42 uncovered a major China-linked hacking campaign targeting foreign ministries’ emails. Fiscal Q4 revenue rose 16% to $2.5 billion, with adjusted EPS up 16% to 95¢. Wall Street maintains a strong buy rating, with price targets averaging $215–220.
8 October 2025
···
Confluent, Inc. (CFLT) – Will a Real‑Time Data Pioneer Become a Takeover Target? (October 8 2025)

Unraveling Confluent (CFLT) Stock: Latest Price, AI‑Driven Buzz & What Experts Say

Confluent closed at $22.84 on Oct. 8, down 10% after Reuters reported the company is exploring a sale following interest from private-equity and tech firms. The stock surged 20% pre-market on the news and remains volatile. Q2 results showed 21% subscription revenue growth, but management warned of slower cloud consumption. Market cap stands near $7.3 billion, with a 52-week range of $15.64 to $37.90.
8 October 2025
··
AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

Recursion Pharmaceuticals’ stock jumped 16% to $6.08 on October 8, 2025, after falling over 5% the previous day. The company uses AI to accelerate drug discovery and recently reported Q2 revenue of $19.2 million, up 33% year-over-year, but posted a net loss of $171.9 million. Recursion holds about $534 million in cash. Recent moves include acquiring Exscientia and cutting several pipeline programs.
8 October 2025
···
1 … 1,329 1,330 1,331 1,332 1,333 … 1,371

Stock Market Today

  • SpaceX IPO Faces Market Skepticism Amid 2021 IPO Value Losses
    April 4, 2026, 7:27 PM EDT. SpaceX's potential IPO arrives in a market wary after the 2021 IPO surge, which saw many offerings lose substantial value. Companies like Allbirds and BuzzFeed have collapsed or sharply declined since their public debuts, wiping out billions in market capitalization. SpaceX stands apart as a scaled, revenue-generating firm with global operations, contrasting with unproven models from the prior boom. However, investor skepticism remains high, especially among retail participants, reflecting caution over past IPO underperformance. The key question is whether SpaceX can revive confidence and demonstrate that IPO investors can still achieve gains after a brutal period of losses.
Go toTop